Clinical Trial Update: Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Plerixafor with G-CSF as conditioning agents before hematopoietic stem cell transplantation in patients with chronic granuloma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatous Disease

Drugs mentioned

• G-CSF (granulocyte colony-stimulating factor)
• Plerixafor (Plerixafor)

Snippet

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Conditions: Chronic Granulomatous Disease | Phase 2 | Status: UNKNOWN